A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9
Status:
Completed
Trial end date:
2016-12-30
Target enrollment:
Participant gender:
Summary
This is a randomized, active-controlled, open-label, sequential dose group, Phase 1b/2 study
designed to assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics
of weekly and every other week doses of GX-H9 in the treatment of AGHD.